{
    "clinical_study": {
        "@rank": "129416", 
        "arm_group": [
            {
                "arm_group_label": "Omega-3", 
                "arm_group_type": "Active Comparator", 
                "description": "This group is receiving omega-3 supplement."
            }, 
            {
                "arm_group_label": "Oil Corn", 
                "arm_group_type": "Placebo Comparator", 
                "description": "This group is receiving the placebo comparador."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this trial is to study the effects of omega-3 PUFA supplementation on the\n      inflammatory response and lipid profile in patients with chronic Chagas cardiomyopathy.\n\n      Study Type: Interventional\n\n      Study Design: A total 40 patients will be randomly assigned into two parallel groups. The\n      intervention will be treatment with omega-3 PUFAs at a dose of 3 g/day for 8 weeks, compared\n      to placebo (corn oil). The primary endpoints will be the concentrations of inflammatory\n      markers (IL-1, IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-\u03b3, and TGF-\u03b2). Secondary endpoints\n      will be the fasting glucose, lipid, and anthropometric profiles."
        }, 
        "brief_title": "Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chagas Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Chagas Cardiomyopathy", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "Several studies have shown the beneficial effects of polyunsaturated fatty acids on\n      inflammatory processes, dyslipidemia, and cardiovascular diseases, there are no reports\n      about food intake and PUFA supplementation in chronic Chagas cardiomyopathy patients. Thus,\n      the objective of this study is to assess the effects of omega-3 PUFA supplementation on the\n      lipid profile and the pro-inflammatory and anti-inflammatory cytokine profiles in chronic\n      Chagas cardiomyopathy patients.\n\n      After patients are selected by cardiologists, they will be seen by study nutritionists, who\n      will explain the study procedures to the patients and administer the free and informed\n      consent form. The patients who agree to participate in the study will sign the consent form\n      and undergo the initial assessment.\n\n      The following data will be collected and evaluated in the study: sociodemographic data (age,\n      sex, ethnicity/race, education, and domicile), clinical data (functional class and vital\n      signs), alcoholism, smoking, prescription drugs, 3-day food record, 24-hour recall,\n      anthropometric assessment (height, weight, BMI, waist circumference, tricipital skinfold\n      thickness, and arm circumference), lipid profile (total cholesterol, triglycerides, HDL-c,\n      LDL-c, and VLDL-c), and cytokines (IL-1, IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-\u03b3, and\n      TGF-\u03b2). Clinical, nutritional, and anthropometric assessments will take place immediately\n      before starting the intervention and after 4 and 8 weeks during the study; lipid profile and\n      cytokines will be evaluated before the intervention and at the end of 8 weeks. Each patient\n      will be followed for 8 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Volunteers with Chagas Cardiomyopathy at stage B (no heart failure symptoms but with\n             segmental or global left ventricular systolic dysfunction), stage C (symptomatic\n             heart failure), or stage D (end-stage heart failure)), according to the current\n             Brazilian Chagas' Disease Consensus;\n\n          -  Subjects will include adults, men and women.\n\n        Exclusion Criteria:\n\n          -  diarrheal disease;\n\n          -  inflammatory bowel syndrome;\n\n          -  diagnosis of diabetes or other endocrine pathologies;\n\n          -  use of fibrates, niacin, or statins;\n\n          -  use of anti-inflammatory drugs;\n\n          -  pregnant and lactating women;\n\n          -  vitamin mineral or omega-3 supplementation during the previous 30 days;\n\n          -  hospital admission during the study;\n\n          -  presence of cardiomyopathies other than Chagas Cardiomyopathy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863576", 
            "org_study_id": "0037.0.009.000-10"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omega-3", 
                "description": "The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.", 
                "intervention_name": "Omega-3", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "Oil fish", 
                    "omega 3 fatty acids", 
                    "polyunsaturated fatty acids"
                ]
            }, 
            {
                "arm_group_label": "Oil Corn", 
                "description": "The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.", 
                "intervention_name": "Placebo Comparador", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Oil Corn"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chagas disease", 
            "Chagas Cardiomyopathy", 
            "Trypanosoma cruzi", 
            "Omega-3", 
            "Cytokines", 
            "Lipid profile", 
            "Nutritional assessment"
        ], 
        "lastchanged_date": "May 23, 2013", 
        "location": {
            "contact": {
                "email": "paula.simplicio@ipec.fiocruz.br", 
                "last_name": "Paula S Simplicio, MSc", 
                "phone": "55 21 38659602"
            }, 
            "contact_backup": {
                "email": "andrea.silvestre@ipec.fiocruz.br", 
                "last_name": "Andrea S Sousa, PhD", 
                "phone": "55 21 38659595"
            }, 
            "facility": {
                "address": {
                    "city": "RJ", 
                    "country": "Brazil", 
                    "state": "Br", 
                    "zip": "21040-360"
                }, 
                "name": "Evandro Chagas Institute of Clinical Research"
            }, 
            "investigator": {
                "last_name": "Paula S Silva, MSc", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy: a Randomized Controlled Clinical Trial", 
        "other_outcome": {
            "description": "The anthropometric assessment will consist of body mass index (BMI), waist circumference, tricipital skinfold thickness, and arm circumference.", 
            "measure": "Anthropometric measures", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "overall_contact": {
            "email": "gilberto.silva@ipec.fiocruz.br", 
            "last_name": "Gilberto Marcelo Sperandio da Silva MS Silva, PhD", 
            "phone": "55 21 38659595"
        }, 
        "overall_contact_backup": {
            "email": "paula.simplicio@ipec.fiocruz.br", 
            "last_name": "Paula S Silva, MSc", 
            "phone": "55 21 38659602"
        }, 
        "overall_official": {
            "affiliation": "Evandro Chagas Institute of Clinical Research", 
            "last_name": "Andrea S Sousa, MD PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of this study will be the cytokine profile. IL-1, IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-\u03b3, and TGF-\u03b2 will be measured in the serum of patients using specific sandwich enzyme-linked immunosorbent assays. Capture and detection antibodies will be obtained from eBioscience (San Diego, CA, USA).", 
            "measure": "Cytokine profile", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863576"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Evandro Chagas Institute of Clinical Research", 
            "investigator_full_name": "Gilberto Marcelo Sperandio da Silva", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-c) will be measured with enzymatic-colorimetric assays using Siemens reagents on a Siemens Dimension RXL chemistry analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). Low-density lipoprotein cholesterol (LDL-c) and VLDL-c will be calculated according to the Friedewald equation", 
            "measure": "Lipid profile", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Evandro Chagas Institute of Clinical Research", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Andrea Silvestre de Sousa, MD PhD", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Alejandro Marcel Hasslocher, MD MSc PhD student", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Andrea Pereira de Souza, PhD", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Claudia Santos de Aguiar Cardoso, MSc", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Patricia Dias de Brito, PhD", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Pedro Emmanuel Alvarenga Americano do Brasil, MD PhD", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Roberta Olmo Pinheiro, PhD", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Roberto Magalh\u00e3es Saraiva, MD PhD", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sergio Salles Xavier, MD PhD", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Paula Simplicio da Silva, MSc", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Evandro Chagas Institute of Clinical Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}